SEC Tracker
Get the app

Equillium EQ

Equillium Q2 FY23: revenue $9.1M; diluted EPS −$0.10

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q
Exhibit 10.1
Material contract
Exhibit 10.2
Material contract

Key figures from this report

These are the numbers Equillium reported for Q2 FY23, the quarter ended Jun 30, 2023, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$9.1MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$3.3MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS−$0.10No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$25.6MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  5. Cash from operations−$6.2MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Equillium files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Zeo ScientifiX ZEOX public float $7M, Apr 30, 2025, over 18 months old
  2. Sunshine Biopharma SBFM public float $7M, Jun 30, 2025
  3. Neuphoria Therapeutics NEUP public float $7M, Dec 31, 2025
  4. CV Sciences CVSI public float $7M, Jun 30, 2025
  5. Minerva Neurosciences NERV public float $7M, Jun 30, 2025